Optimi Health Corp. · NASDAQ Capital · priced May 20, 2026 · $15M raised · Under $50M
Price since listing
- Hype
- Distribution
- Lock-up window
- Valley
- Accumulation
- Recovery
Volume bars are coloured by lifecycle phase. Markers: lock-up and early release (orange), earnings releases (E), follow-on offerings (F), research signals (rule id and signal; arrow up = buy signal, arrow down = sell or short signal, or sell signal for deals under $50M). Current phase: Lock-up window.
Performance since the IPO
- OPTH
- S&P 500 (SPY)
- Typical IPO under $50m
- Middle 50% of those IPOs
OPTH measured from its offer price; S&P 500 from the first trading day. The typical-IPO line is the median of 382 under $50m IPOs from 2014–2025, by trading day.
Company
Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Employees
- —
- Market cap
- $17M
- Website
- www.optimihealth.ca
From the prospectus
- Lock-up
- 180 days
- Early release on earnings
- No
- Price-based early release
- No
- Staggered release
- No
- Float sold in IPO
- 43%
- Locked shares per share sold
- 1.3×
- Backed by
- Founder or family
- Lead underwriters
- Joseph Gunnar & Co., LLC
- Dual-class shares
- No
- Controlled company
- No
- Foreign private issuer
- Yes
Extracted from the final prospectus on SEC EDGAR.
Returns vs offer, compared with 189 IPOs under $50m
| Horizon | OPTH | Peer median | Peers below offer |
|---|---|---|---|
| Day 1 | -2.7% | 0.0% | 47% n=189 |
| Day 20 | -30.2% | -10.3% | 61% n=187 |
| Day 60 | -23.4% | -34.4% | 70% n=184 |
| Day 120 | — | -51.8% | 78% n=177 |
| Day 180 | — | -68.7% | 83% n=174 |
Research signals
- SellRule F1: sell signal for 100 sessionsJun 17, 2026 · Microcap dealPast signals (387, deals under $50M): fell 73% · median -29.0% · rallied 25%+ during the hold 50%backtest
Deal under $50M: published as a sell signal only, because shorting such shares is usually impractical (hard to borrow, high borrow fees, frequent squeezes).
- SellRule R20: sell signal for 100 sessionsJun 17, 2026 · Day-20 risk tierPast signals (280, deals under $50M): fell 76% · median -33.9% · rallied 25%+ during the hold 50%backtest
Deal under $50M: published as a sell signal only, because shorting such shares is usually impractical (hard to borrow, high borrow fees, frequent squeezes).
Rules frozen as v1; signals dated from Oct 29, 2026 are live, earlier ones show what the frozen rules would have flagged. See methodology.
Past figures cover all 4,312 signals the published frozen v1 rules produce on 2014–2025 IPOs, close to close over each signal's holding period. Returns start at the close of the signal session; signals are published after that close, so the first price available to a reader is the next session's. Only 1,192 of 2,368 operating-company IPOs from those years have usable Yahoo Finance price data; most of the rest no longer trade under their IPO ticker (delisted, acquired or renamed), so the figures probably understate declines. These are hypothetical results, not trades: the rules were selected on these same years with the benefit of hindsight, so the figures likely overstate what live signals will do. The live track record is the real test. Trading costs and borrow fees are not included. Past results do not predict future results.
Research signals only, not investment advice. Lock-up terms come from prospectuses; prices from Yahoo Finance and may be delayed or wrong.